IMCR

$0.00

(

0.00%

)
Quote details

stock

Immunocore Holdings Ltd

NASDAQ | IMCR

32.35

USD

$0.00

(

0.00%

)

At Close (As of Oct 13, 2025)

$1.63B

Market Cap

-

P/E Ratio

-0.41

EPS

$39.33

52 Week High

$23.15

52 Week Low

HEALTHCARE

Sector

IMCR Chart

Recent Chart
Price Action

IMCR Technicals

Tags:

IMCR Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $307M
Total Revenue $310M
Cost Of Revenue $2.7M
Costof Goods And Services Sold $2.7M
Operating Income -$70M
Selling General And Administrative $156M
Research And Development $222M
Operating Expenses $378M
Investment Income Net -
Net Interest Income $6.8M
Interest Income $26M
Interest Expense $19M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.4M
Income Before Tax -$53M
Income Tax Expense -$1.9M
Interest And Debt Expense -
Net Income From Continuing Operations -$51M
Comprehensive Income Net Of Tax -
Ebit -$42M
Ebitda -$39M
Net Income -$51M

Revenue & Profitability

Earnings Performance

IMCR Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $1B
Total Current Assets $930M
Cash And Cash Equivalents At Carrying Value $456M
Cash And Short Term Investments $456M
Inventory $5.4M
Current Net Receivables $83M
Total Non Current Assets $80M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $365M
Other Current Assets $21M
Other Non Current Assets -
Total Liabilities $649M
Total Current Liabilities $212M
Current Accounts Payable $25M
Deferred Revenue -
Current Debt -
Short Term Debt $1.5M
Total Non Current Liabilities $437M
Capital Lease Obligations $42M
Long Term Debt $391M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $433M
Other Current Liabilities $186M
Other Non Current Liabilities -
Total Shareholder Equity $361M
Treasury Stock -
Retained Earnings -$796M
Common Stock $135K
Common Stock Shares Outstanding $50M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow $26M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $4.2M
Capital Expenditures $5.2M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$355M
Cashflow From Financing $344M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$51M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $307M
Total Revenue $310M
Cost Of Revenue $2.7M
Costof Goods And Services Sold $2.7M
Operating Income -$70M
Selling General And Administrative $156M
Research And Development $222M
Operating Expenses $378M
Investment Income Net -
Net Interest Income $6.8M
Interest Income $26M
Interest Expense $19M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.4M
Income Before Tax -$53M
Income Tax Expense -$1.9M
Interest And Debt Expense -
Net Income From Continuing Operations -$51M
Comprehensive Income Net Of Tax -
Ebit -$42M
Ebitda -$39M
Net Income -$51M

IMCR News

IMCR Profile

Immunocore Holdings Ltd Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Immunocore Holdings Limited is an advanced-stage biotechnology company based in Abingdon, UK, specializing in the development of innovative immunotherapies targeting cancer, infectious diseases, and autoimmune disorders. Leveraging its proprietary T cell receptor technology, Immunocore is focused on harnessing the body's immune system to develop transformative therapies that aim to improve patient outcomes. With a robust pipeline of clinical programs and strategic partnerships, the company is well-positioned to be a leader in the rapidly evolving immunotherapy landscape.

VHAI
-25.00%
$0.00
YYAI
-10.47%
$0.17
STAI
+39.44%
$0.62
BURU
+7.15%
$0.50
CGBS
-39.47%
$0.03
ELBM
+325.45%
$7.02
PLUG
+14.03%
$3.90
INTC
-3.78%
$36.36
RGTI
+25.02%
$54.91
GWH
+118.14%
$9.07
NVDA
+2.81%
$188.32
BITF
+28.33%
$5.39
ASST
-30.54%
$1.08
IONZ
-32.55%
$2.29
BYND
-48.50%
$1.03
NVTS
+21.14%
$9.97
JOBY
+2.94%
$16.76
DNN
+7.11%
$3.08
EPWK
-21.60%
$0.09
GPUS
-12.48%
$0.42
QBTS
+22.83%
$40.56
CAN
+33.93%
$1.45
SNAP
-7.15%
$7.78
F
+1.18%
$11.54
WULF
-0.58%
$13.51
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
PFE
-1.82%
$24.78
CRML
+55.40%
$23.28
TSLA
+5.01%
$434.23
QS
+15.57%
$16.98
SOFI
+3.62%
$27.14
ETHD
-12.95%
$3.32
RXRX
+3.94%
$5.53
NIO
+6.59%
$7.15
APLD
+0.73%
$34.24
RR
-9.34%
$5.92
TLRY
-1.74%
$1.69
ACHR
+6.09%
$12.70
DFLI
+44.03%
$1.57
AMD
+0.40%
$215.76
QUBT
-10.81%
$19.01
PWM
+12.50%
$1.17
NAK
+29.80%
$2.63
SOUN
+10.25%
$19.14
LAES
+13.30%
$6.13
ONDS
+17.24%
$10.81
DVLT
-10.52%
$1.70
CIFR
+19.77%
$20.32
USAR
+18.61%
$38.68
MP
+21.94%
$95.52
BTBT
+5.58%
$3.97
IREN
+7.31%
$64.14
NAKA
-1.56%
$0.85
RIG
+3.73%
$3.19
WBD
-3.22%
$17.10
UAMY
+36.85%
$16.71
NOK
-1.50%
$5.24
ABAT
+33.25%
$8.99
UUUU
+16.88%
$23.77
MARA
+8.52%
$20.23
EOSE
+23.37%
$17.05
PLTR
+1.00%
$177.21
RMBL
+60.50%
$3.21
ADD
-25.47%
$0.05
ADAP
-0.64%
$0.18
XCH
+103.41%
$1.68
AAL
+1.51%
$11.69
TMQ
-9.46%
$5.93
BULL
+2.98%
$11.74
T
-1.14%
$25.57
RF
+1.63%
$24.55
SRM
+53.27%
$10.30
GDXD
-13.54%
$0.73
IONQ
+18.72%
$83.88
GOOGL
-2.05%
$236.57
QSI
+24.55%
$2.08
BMNR
+7.40%
$56.35
CLF
-7.18%
$13.18
VALE
+2.37%
$11.00
CLSK
+2.49%
$19.76
SMR
+14.72%
$45.02
BINI
-55.00%
$0.63
MULN
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
RGTZ
-50.00%
$9.30
SLB
+1.71%
$32.26
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
ORCL
-1.34%
$292.95
ABEV
+1.18%
$2.13
NEHC
-8.12%
$2.60
BE
+26.54%
$109.93
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
TMC
+20.31%
$10.69
KDLY
-7.21%
$0.87
ETWO
0.00%
$3.30
AAPL
+1.24%
$248.32
VHAI
-25.00%
$0.00
YYAI
-10.47%
$0.17
STAI
+39.44%
$0.62
BURU
+7.15%
$0.50
CGBS
-39.47%
$0.03
ELBM
+325.45%
$7.02
PLUG
+14.03%
$3.90
INTC
-3.78%
$36.36
RGTI
+25.02%
$54.91
GWH
+118.14%
$9.07
NVDA
+2.81%
$188.32
BITF
+28.33%
$5.39
ASST
-30.54%
$1.08
IONZ
-32.55%
$2.29
BYND
-48.50%
$1.03
NVTS
+21.14%
$9.97
JOBY
+2.94%
$16.76
DNN
+7.11%
$3.08
EPWK
-21.60%
$0.09
GPUS
-12.48%
$0.42
QBTS
+22.83%
$40.56
CAN
+33.93%
$1.45
SNAP
-7.15%
$7.78
F
+1.18%
$11.54
WULF
-0.58%
$13.51
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
PFE
-1.82%
$24.78
CRML
+55.40%
$23.28
TSLA
+5.01%
$434.23
QS
+15.57%
$16.98
SOFI
+3.62%
$27.14
ETHD
-12.95%
$3.32
RXRX
+3.94%
$5.53
NIO
+6.59%
$7.15
APLD
+0.73%
$34.24
RR
-9.34%
$5.92
TLRY
-1.74%
$1.69
ACHR
+6.09%
$12.70
DFLI
+44.03%
$1.57
AMD
+0.40%
$215.76
QUBT
-10.81%
$19.01
PWM
+12.50%
$1.17
NAK
+29.80%
$2.63
SOUN
+10.25%
$19.14
LAES
+13.30%
$6.13
ONDS
+17.24%
$10.81
DVLT
-10.52%
$1.70
CIFR
+19.77%
$20.32
USAR
+18.61%
$38.68
MP
+21.94%
$95.52
BTBT
+5.58%
$3.97
IREN
+7.31%
$64.14
NAKA
-1.56%
$0.85
RIG
+3.73%
$3.19
WBD
-3.22%
$17.10
UAMY
+36.85%
$16.71
NOK
-1.50%
$5.24
ABAT
+33.25%
$8.99
UUUU
+16.88%
$23.77
MARA
+8.52%
$20.23
EOSE
+23.37%
$17.05
PLTR
+1.00%
$177.21
RMBL
+60.50%
$3.21
ADD
-25.47%
$0.05
ADAP
-0.64%
$0.18
XCH
+103.41%
$1.68
AAL
+1.51%
$11.69
TMQ
-9.46%
$5.93
BULL
+2.98%
$11.74
T
-1.14%
$25.57
RF
+1.63%
$24.55
SRM
+53.27%
$10.30
GDXD
-13.54%
$0.73
IONQ
+18.72%
$83.88
GOOGL
-2.05%
$236.57
QSI
+24.55%
$2.08
BMNR
+7.40%
$56.35
CLF
-7.18%
$13.18
VALE
+2.37%
$11.00
CLSK
+2.49%
$19.76
SMR
+14.72%
$45.02
BINI
-55.00%
$0.63
MULN
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
RGTZ
-50.00%
$9.30
SLB
+1.71%
$32.26
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
ORCL
-1.34%
$292.95
ABEV
+1.18%
$2.13
NEHC
-8.12%
$2.60
BE
+26.54%
$109.93
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
TMC
+20.31%
$10.69
KDLY
-7.21%
$0.87
ETWO
0.00%
$3.30
AAPL
+1.24%
$248.32

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.